Ying-Wei Chang, Li Fan, Guo-Tong Sun, Cai-Yun Yang, Xiu-Wen Liang, Ying Zhang, Hong-Feng He
{"title":"山黄降脂片联合阿托伐他汀钙片治疗颈动脉粥样硬化的临床疗效回顾性队列研究。","authors":"Ying-Wei Chang, Li Fan, Guo-Tong Sun, Cai-Yun Yang, Xiu-Wen Liang, Ying Zhang, Hong-Feng He","doi":"10.1186/s41043-025-01057-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The efficacy and safety of the combination therapy of Shanhuang Jiangzhi tablets and atorvastatin in treating primary hyperlipidemia and carotid atherosclerosis remain unclear and require further investigation.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was conducted using the medical records of the neurology wards from 1 January 2014 to 30 June 2022. Patients were divided into observation and control groups based on inclusion and exclusion criteria. The control group received atorvastatin calcium tablets at a dose of 20 mg per day, whereas the observation group received the same dose of atorvastatin plus Shanhuang Jiangzhi tablets at 2.4 g per day. The treatment period for both groups was 2 years. Blood lipid profiles and carotid ultrasound indicators were compared before and after treatment. All the data were statistically analysed using SPSS 26.0.</p><p><strong>Results: </strong>This study included 319 atherosclerosis patients, with 162 in the observation group (average age 62.84 ± 11.90 years, 44.4% men) and 157 in the control group (average age 62.62 ± 10.33 years, 52.2% men). No significant differences were found in baseline characteristics between the two groups (p > 0.05). Following treatment, significant reductions in total cholesterol (4.38 ± 1.07 vs. 4.71 ± 1.11) and low-density lipoprotein cholesterol levels (2.78 ± 0.80 vs. 3.11 ± 0.92) were observed in the observation group compared with the control group (p < 0.05). Additionally, improvements in the carotid intima-media thickness (IMT) (1.63 ± 0.09 vs. 1.80 ± 0.05) and plaque scores (4.06 ± 0.26 vs. 4.17 ± 0.29) were more pronounced in the observation group (p < 0.05).</p><p><strong>Conclusion: </strong>This study investigated the use of Shanhuang Jiangzhi tablets combined with atorvastatin calcium for carotid atherosclerosis, offering effective options for traditional Chinese medicine in managing atherosclerosis and hyperlipidaemia.</p>","PeriodicalId":15969,"journal":{"name":"Journal of Health, Population, and Nutrition","volume":"44 1","pages":"324"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465801/pdf/","citationCount":"0","resultStr":"{\"title\":\"A retrospective cohort study on the clinical efficacy of Shanhuang Jiangzhi tablets and Atorvastatin calcium tablets in the treatment of carotid atherosclerosis.\",\"authors\":\"Ying-Wei Chang, Li Fan, Guo-Tong Sun, Cai-Yun Yang, Xiu-Wen Liang, Ying Zhang, Hong-Feng He\",\"doi\":\"10.1186/s41043-025-01057-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The efficacy and safety of the combination therapy of Shanhuang Jiangzhi tablets and atorvastatin in treating primary hyperlipidemia and carotid atherosclerosis remain unclear and require further investigation.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was conducted using the medical records of the neurology wards from 1 January 2014 to 30 June 2022. Patients were divided into observation and control groups based on inclusion and exclusion criteria. The control group received atorvastatin calcium tablets at a dose of 20 mg per day, whereas the observation group received the same dose of atorvastatin plus Shanhuang Jiangzhi tablets at 2.4 g per day. The treatment period for both groups was 2 years. Blood lipid profiles and carotid ultrasound indicators were compared before and after treatment. All the data were statistically analysed using SPSS 26.0.</p><p><strong>Results: </strong>This study included 319 atherosclerosis patients, with 162 in the observation group (average age 62.84 ± 11.90 years, 44.4% men) and 157 in the control group (average age 62.62 ± 10.33 years, 52.2% men). No significant differences were found in baseline characteristics between the two groups (p > 0.05). Following treatment, significant reductions in total cholesterol (4.38 ± 1.07 vs. 4.71 ± 1.11) and low-density lipoprotein cholesterol levels (2.78 ± 0.80 vs. 3.11 ± 0.92) were observed in the observation group compared with the control group (p < 0.05). Additionally, improvements in the carotid intima-media thickness (IMT) (1.63 ± 0.09 vs. 1.80 ± 0.05) and plaque scores (4.06 ± 0.26 vs. 4.17 ± 0.29) were more pronounced in the observation group (p < 0.05).</p><p><strong>Conclusion: </strong>This study investigated the use of Shanhuang Jiangzhi tablets combined with atorvastatin calcium for carotid atherosclerosis, offering effective options for traditional Chinese medicine in managing atherosclerosis and hyperlipidaemia.</p>\",\"PeriodicalId\":15969,\"journal\":{\"name\":\"Journal of Health, Population, and Nutrition\",\"volume\":\"44 1\",\"pages\":\"324\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465801/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Health, Population, and Nutrition\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s41043-025-01057-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENVIRONMENTAL SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health, Population, and Nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s41043-025-01057-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENVIRONMENTAL SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景：山黄降脂片联合阿托伐他汀治疗原发性高脂血症和颈动脉粥样硬化的疗效和安全性尚不清楚，有待进一步研究。材料与方法：采用2014年1月1日至2022年6月30日神经内科病房的病历资料进行回顾性队列研究。根据纳入标准和排除标准将患者分为观察组和对照组。对照组患者给予阿托伐他汀钙片，剂量为20mg / d，观察组患者给予相同剂量的阿托伐他汀加山黄降脂片，剂量为2.4 g / d。两组治疗时间均为2年。比较治疗前后血脂及颈动脉超声指标。所有数据采用SPSS 26.0进行统计学分析。结果：共纳入319例动脉粥样硬化患者，其中观察组162例（平均年龄62.84±11.90岁，男性44.4%），对照组157例（平均年龄62.62±10.33岁，男性52.2%）。两组患者基线特征差异无统计学意义（p < 0.05）。治疗后，观察组总胆固醇（4.38±1.07比4.71±1.11）、低密度脂蛋白胆固醇水平（2.78±0.80比3.11±0.92）较对照组显著降低(p)。结论：本研究探讨山黄降脂片联合阿托伐他汀钙治疗颈动脉粥样硬化，为中医药治疗动脉粥样硬化及高脂血症提供有效选择。
A retrospective cohort study on the clinical efficacy of Shanhuang Jiangzhi tablets and Atorvastatin calcium tablets in the treatment of carotid atherosclerosis.
Background: The efficacy and safety of the combination therapy of Shanhuang Jiangzhi tablets and atorvastatin in treating primary hyperlipidemia and carotid atherosclerosis remain unclear and require further investigation.
Materials and methods: A retrospective cohort study was conducted using the medical records of the neurology wards from 1 January 2014 to 30 June 2022. Patients were divided into observation and control groups based on inclusion and exclusion criteria. The control group received atorvastatin calcium tablets at a dose of 20 mg per day, whereas the observation group received the same dose of atorvastatin plus Shanhuang Jiangzhi tablets at 2.4 g per day. The treatment period for both groups was 2 years. Blood lipid profiles and carotid ultrasound indicators were compared before and after treatment. All the data were statistically analysed using SPSS 26.0.
Results: This study included 319 atherosclerosis patients, with 162 in the observation group (average age 62.84 ± 11.90 years, 44.4% men) and 157 in the control group (average age 62.62 ± 10.33 years, 52.2% men). No significant differences were found in baseline characteristics between the two groups (p > 0.05). Following treatment, significant reductions in total cholesterol (4.38 ± 1.07 vs. 4.71 ± 1.11) and low-density lipoprotein cholesterol levels (2.78 ± 0.80 vs. 3.11 ± 0.92) were observed in the observation group compared with the control group (p < 0.05). Additionally, improvements in the carotid intima-media thickness (IMT) (1.63 ± 0.09 vs. 1.80 ± 0.05) and plaque scores (4.06 ± 0.26 vs. 4.17 ± 0.29) were more pronounced in the observation group (p < 0.05).
Conclusion: This study investigated the use of Shanhuang Jiangzhi tablets combined with atorvastatin calcium for carotid atherosclerosis, offering effective options for traditional Chinese medicine in managing atherosclerosis and hyperlipidaemia.
期刊介绍：
Journal of Health, Population and Nutrition brings together research on all aspects of issues related to population, nutrition and health. The journal publishes articles across a broad range of topics including global health, maternal and child health, nutrition, common illnesses and determinants of population health.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
